Helping You Build Wealth With Honest Research
Since 1996. Read On...

MEMBER'S LOGIN

MEMBER'S LOGINX

     
Invalid Username / Password
   
     
   
     
 
Invalid Captcha
   
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

Revealed
India's Third Giant Leap

This Could be One of the Biggest Opportunities for Investors




Important: We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
By submitting your email address, you also sign up for Profit Hunter, a daily newsletter from Equitymaster
covering exciting investing ideas and opportunities in India.

AD

Auto, energy stocks lead the gains
Thu, 15 Oct Closing

Buoyed by strong sentiments across Asia and Europe, Indian stock markets performed well today and ended well above the dotted line. While the BSE-Sensex closed higher by around 230 points, gains on the NSE-Nifty came in at around 72 points. S&P BSE Midcap and S&P BSE Smallcap indices also closed strong, edging higher by around 0.8% and 0.5% respectively. Auto and oil and gas stocks emerged as the top gainers.

Asian markets closed sharply higher today with shares in China leading the region. The Shanghai Composite was up 2.32% while Hong Kong's Hang Seng was up 2.00%. Japan's Nikkei 225 closed higher by 1.15%. European markets have opened higher in early trade with shares in Germany leading the gains. The rupee was trading weak at 65.11 against the US$ in the afternoon session.

Healthcare sector finished the day with modest gains with IPCA Labs and Opto Circuits leading the gains. According to a leading financial daily, Swiss pharmaceutical firm Helsinn Healthcare SA has settled patent litigations relating to its anti-nausea injection Aloxi with Dr. Reddy's Laboratories Ltd. The settlement will allow Dr. Reddy's to market the generic version of Aloxi in the US on 30 September 2018 or earlier under certain circumstances. Aloxi generically called as palonosetron HCl injection is used to treat chemotherapy-induced nausea and vomiting in patients suffering from cancer. Reportedly, Aloxi had sales of nearly US$416 million in the US and Canada for the year ended 31 March.

Radhika Pandit, Managing Editor of ValuePro recently wrote an article in the '5 Minute Wrap Up Premium' highlighting the issues faced by Dr Reddy's. The article gives an in depth view of the company's delay in product launch.

Tata Consultancy Services (TCS) is reportedly in talks with nine of the 11 payments bank license holders to offer operational solutions. The company has been a key participant for government deals in the domestic market. In the banking sector, it works with most of the leading lenders. State Bank of India, the largest public sector bank, has its core banking operations on TCS' banking platform, BaNCS.

Tata Consultancy Services has announced its financial results for 2QFY16. The company has reported a 5.8% quarter-on-quarter (QoQ) increase in its consolidated sales and a 6.5% QoQ increase in its consolidated net profit in 2QFY16. Here is our analysis of the results.

For information on how to pick stocks that have the potential to deliver big returns, download our special report now!

View all commentaries | Archives

Read the latest Market Commentary


Equitymaster requests your view! Post a comment on "Auto, energy stocks lead the gains". Click here!

  
ABOUT EQUITYMASTER

Since 1996, Equitymaster has been the source for honest and credible opinions on investing in India. With solid research and in-depth analysis Equitymaster is dedicated towards making its readers- smarter, more confident and richer every day. Here's why hundreds of thousands of readers spread across more than 70 countries Trust Equitymaster.

PREMIUM PRODUCTS
QUICK LINKS
POPULAR TOPICS
TRENDING TOPICS
FREE NEWSLETTERS
EQUITYMASTER SUPPORTS
  • HelpYourNGO
  • You Tube
  • Linkedin
  • Twitter
  • Telegram
  • Google Play

Copyright © Equitymaster Research Private Limited (formerly Equitymaster Agora Research Private Limited).

Whitelist | Refer | Terms | Privacy | Contact | About | Sitemap

Phone +91-9136015013

Equitymaster Research Private Limited (formerly Equitymaster Agora Research Private Limited) (Research Analyst)
SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.

103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
Telephone: +91-22-61434055. Email: info@equitymaster.com. Website: www.equitymaster.com.
CIN:U74999MH2007PTC175407

Name of the Compliance & Grievance Officer: Ms Sonal Ramachandran
Telephone: +91-22-61434003 | Email: compliance@equitymaster.com

LEGAL DISCLAIMER:
Investment in securities market are subject to market risks. Read all the related documents carefully before investing.
Registration granted by SEBI and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.

All rights reserved. Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.

Equitymaster Research Private Limited (formerly Equitymaster Agora Research Private Limited) (Research Analyst) bearing Registration No. INH000000537 (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA, Canada or the European Union countries, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.